

MINUTES OF PRE-BID MEETING

Brief Description of Procurement

Sch. No.	Description of Goods/drugs	No. of Tablets
I	Nevirapine 200 mg	88,66,736
II	Ziduvudine 300 mg + Lamivudine 150 mg	5,28,64,774
III	Tenofovir 300 mg + Lamivudine 300 mg	3,31,62,822
IV	Lopinavir 200 mg + Ritonavir 50 mg	1,90,36,783

IFB No.

SAMS/NACP/ARV DRUGS (4 ITEMS)/14/2016

Date of Publication of Notification

17.10.2016

Date and Time of Pre-Bid Meeting

8th November 2016 at 15.00 Hrs.

Venue of Pre-Bid Meeting

Strategic Alliance Management Services Pvt. Ltd.
B01-B03, Vardhman Diamond Plaza,
Community Centre, D.B. Gupta Road, Paharganj,
New Delhi- 110055

Date of Bid submission

02.12.2016

The following Bidders' Representatives attended the pre-bid meeting:

Sr. No.	Name and Designation	Name of Prospective Bidder/Firm
1.	Mr. J. B. Pal	M/s Macleods Pharma Ltd., Mumbai
2.	Mr. Onkar Yadav	M/s Maan Pharmaceuticals Ltd., Ahmedabad
3.	Mr. Arun Sharma	M/s Mylan Laboratories Ltd., Hyderabad

The following officials from SAMS's were present in the pre-bid meeting:

Sr. No.	Name and Designation
1.	Mr. Anil K. Bhutani, GM (Procurement) & Team Leader
2.	Mr. Satya P. Verma, General Manager (Procurement)
3.	Mr. Arpit Saxena, Manager (Procurement & SCM)

Proceedings of the pre-bid meeting are as follows;

1. At the outset, General Manager (Procurement), SAMS briefed about the purpose of the pre-bid meeting.
2. Thereafter, prospective bidders were requested to put up their queries related to scope and terms and conditions given in the Bid Document.
3. The queries from prospective bidders were appropriately responded. The representatives were also requested to send their queries in writing through e-mail within 2 days.
4. The responses to queries sought by prospective bidders in writing and those asked during the meeting have been compiled as **Clarifications 1 (Annexure-A)** in pursuance to ITB Clause 11 of the Bid Document.



(A.K. Bhutani)
GM (Procurement) & Team Leader

CLARIFICATIONS - 1


DATED 24.11.2016

Response to requests for clarification / queries received from prospective bidders


1. IFB Reference: SAMS/NACP/ARV DRUGS (4 ITEMS)/14/2016
2. Date of Publication/Notification: 17/10/2016
3. Date of Pre-bid meeting: 08/11/2016
4. Date of Bid Submission: 02/12/2016

As per provisions given in ITB Clause 11 of the Bid Document and the queries/suggestions sought by the prospective bidders, the following responses are being issued:-


Sl. No.	Clause reference / Page reference	Queries / Clarifications sought by the prospective bidders	Para/ Clause as per Bid Document	Response
1	Invitation for Bids (IFB) Para 2, Schedule I (Tablet Nevirapine 200 mg), Page 5 Schedule of requirement]Schedule I, Page 82 and Delivery Schedule- Schedule I Page 82 Schedule I Lot I & Lot II, Pages 83 & 84	Typographical error	Quantity in no. of Tablets- 88,68,733 Quantity in no. of Tablets- 88,68,733 Lot 1- 30,90,133 Lot 2- 57,78,600	Quantity in no. of Tablets- 88,66,736 Quantity in no. of Tablets- 88,66,736 Lot 1- 30,90,133 Lot 2- 57,76,603
2	Section II: Bid data Sheet Para 7.1.a.5.c. (page no. 39)	Requested to give relaxation in clause 7.1.a.5.c I.e. instead of three years' experience for similar goods it should be two year experience.	has manufactured and marketed the specific good covered by the bidding document for at least One (1) years , and for similar goods (viz. Tablets/ Capsules/ Syrup) for at least three (3) years . In support of this, data on past performance should be submitted as per Form 11 in Section VIII	No change in qualification of bidder. No change in the Bid Document.
3	Section II: Bid Data Sheet	Typographical error	Required number of copies of the bid: 02	It is clarified that the required number of copies of the bid: 02



Sl. No.	Clause reference / Page reference	Queries / Clarifications sought by the prospective bidders	Para/ Clause as per Bid Document	Response
	ITB 21.1 (Page no. 46)		(One original + Two copies). In addition, bidder shall submit a copy of the bid in CD/ Pen-drive.	(One original + one copy). In addition, bidder shall submit a copy of the bid in CD/ Pen-drive.
4	Section IV: General Conditions of Contract (GCC) – Para 10.2. (page no. 59)	“Secondary Container:- We have observed that if we pack 140 bottles in a shipper, the weight of the shipper 25-30 kgs., which will be too high to handle during loading, unloading & transportation activities. There is no cost involved & all remains same as per the terms & conditions. Hence we request you to kindly amend from 140 to 30 Bottles per Shipper to avoid damages and lashes during transit. We made the previous supplies to RITES/NACO for this product. Amendment issued by M/s RITES is enclosed for your ready reference.	The packing, marking, and documentation within and outside the packages shall comply strictly with such special requirements as shall be expressly provided for in the Contract, including additional requirements, if any, specified in the SCC or Technical Specifications, and in any subsequent instructions ordered by the Purchaser.	No change in the Bid document.
5	Section IV: Payments: ITB Clause 16.3 of General Conditions of Contract (GCC) (Page no. 62)	Please ensure the payments to be cleared within 60 days from the date of submission of Invoices. For any delays in payments beyond 60 days a levy at the prevailing bank rates will have to be accepted as compensation by RITES.	Payments shall be made promptly by the Purchaser, but in no case later than sixty (60) days after submission of an invoice or claim by the Supplier.	No change in the Bid document.
6	Section V: Para 22.1 of SCC. (page no. 78)	The bidders requested that LD @ 0.50 % per week is quite steep for any standards and requested that for delays beyond the agreed lead times can be 0.25% per month.	Applicable rate of LD is 0.5 percent per week or part thereof. Maximum deduction shall be 10 percent of the delivered price of the delayed goods.	No change in the Bid document.
7	Section VI: Schedule of requirements for ARV Drugs (page no. 82)	Typographical error	Delivery Schedule for supply of Tablet Abacavir 600 mg + Lamivudine 300 mg	It should be read as follows: Delivery Schedule for supply of Tablets
8	Section VI: Schedule of	The bidders informed that for 1st tranche of 1 st	1st tranche of 1 st lot of each schedule	No change in the Schedule of supply.



Sl. No.	Clause reference / Page reference	Queries / Clarifications sought by the prospective bidders	Para/ Clause as per Bid Document	Response
	Requirements for ARV Drugs: Delivery Schedule for supply of Tablets- Schedule I to IV- (Page no. 82 – 3 rd Column and 5 th columns on each of pages 83,85,87 and 89))	lot of each schedule, a minimum lead time of 90 days is required to arrange API, approval of art works etc. They requested for amending the delivery period as 90 days from the date of notification of award for 1st tranche of 1 st lot quantity as against 60 days.	indicated on the 3 rd column at Page 82, and 5 th Column on pages 83,85,87 and 89 for Schedules I to IV to be delivered within 60 days from the date of issue of Notification of Award (NOA).	As such no change in the Bid Document.
9	Section VII: Technical Specifications Schedule – III Tablet Lopinavir 200mg + Ritonavir 50 mg (page no. 99)	For Schedule III – Tablet Tenofovir 300 mg + Lamivudine 150 mg- currently all the suppliers are manufacturing the product as follows. Tenofovir Disoproxil Fumarate 300 mg IP or any other pharmacopoeia Lamivudine 300 mg IP or any other pharmacopoeia	Para 1 of Schedule III: • Tenofovir Disoproxil Fumarate 300 mg IP or any other pharmacopoeia • Lamivudine 150 mg IP or any other pharmacopoeia	Para 1 of Schedule III should be read as: • Tenofovir Disoproxil Fumarate 300 mg IP or any other pharmacopoeia • Lamivudine 300 mg IP or any other pharmacopoeia (Typographical error)
10	Section VII: Technical Specifications Schedule – IV Tablet Lopinavir 200mg + Ritonavir 50 mg (page no. 100)	Typographical error	Para 1: Each tablet/ capsule contains • Lopinavir 300 mg IP or any other pharmacopoeia • Ritonavir 50 mg IP or any other pharmacopoeia	Para 1: Each tablet/ capsule contains • Lopinavir 200 mg IP or any other pharmacopoeia • Ritonavir 50 mg IP or any other pharmacopoeia



Anil Kr. Bhutani
GM (Procurement) & Team Leader